Pertuzumab–Docetaxel–Trastuzumab regimen in HER2-positive metastatic breast cancer: Real-world data from India
Purpose: Dual human epidermal growth factor receptor 2 (HER2) blockade with pertuzumab and trastuzumab plus chemotherapy is the standard first-line treatment for HER2-positive metastatic breast cancer (BC), as per the CLEOPATRA trial. However, real-world data from low- and middle-income countries (L...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2026-01-01
|
| シリーズ: | Cancer Treatment and Research Communications |
| 主題: | |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S2468294226001073 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|